CN101686968B - 7-乙基-10-羟基喜树碱的多晶型物 - Google Patents
7-乙基-10-羟基喜树碱的多晶型物 Download PDFInfo
- Publication number
- CN101686968B CN101686968B CN2008800217514A CN200880021751A CN101686968B CN 101686968 B CN101686968 B CN 101686968B CN 2008800217514 A CN2008800217514 A CN 2008800217514A CN 200880021751 A CN200880021751 A CN 200880021751A CN 101686968 B CN101686968 B CN 101686968B
- Authority
- CN
- China
- Prior art keywords
- solvent
- ethyl
- hydroxycamptothecine
- mixture
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Battery Electrode And Active Subsutance (AREA)
Abstract
一种7-乙基-10-羟基喜树碱的多晶型物,其X-射线衍射图在10.9±0.2、13.2±0.2、23.9±0.2和26.1±0.22θ度处有峰。
Description
相关申请
本申请要求2007年6月25日提交的美国临时专利申请60/937,098的优先权。本文引入该临时专利申请的全部内容作为参考。
技术领域
本发明涉及7-乙基-10-羟基喜树碱的新晶型、相应的药物组合物及其制备方法和/或用于治疗抗病毒和/或与癌有关的疾病的方法。
背景技术
伊立替康是一种用于治疗某些类型癌症的化疗药物。最常用于治疗肠癌。当给病人施加药物时,伊立替康代谢为一更活性的代谢物,7-乙基-10-羟基喜树碱,也被称为SN38。SN38本身目前也被当作化疗药物而研究,其化学结构如下:
有必要开发一种更适合用于药物用途的改进型的SN38。
发明内容
我们发现了SN38的一种新晶型及其制备方法。
根据本发明的一个具体体现,SN38的多晶型物表现为其X-射线衍射图在10.9±0.2、13.2±0.2、23.9±0.2和26.1±0.22θ度处有峰。
优选的,其X-射线衍射图还在10.4±0.2、16.8±0.2、17.7±0.2、24.6±0.2和26.7±0.22θ度处有峰。更优选的,其X-射线衍射图还在12.9±0.2、16.2±0.2、17.6±0.2、20.9±0.2、22.3±0.2和33.3±0.22θ度处有峰。
根据本发明的另一具体体现,该多晶型物表现为其X-射线衍射图如图1所示。
根据本发明的另一方面,该多晶型物表现为其红外图谱有位于3584±2cm-1、3253±2cm-1和1736±2cm-1处的谱带。
优选的,该红外图谱还有位于1653±2cm-1、1514±2cm-1和1173±2cm-1的谱带。更优选的,多晶型的红外图谱如图2所示。
有效量的上文所讨论的晶体SN38能与至少一药学上可接受的载体混合以形成一药物组合物。
根据本发明的另一方面,我们开发了一种制备晶体SN38的方法,包括:
(1)将粗SN38溶解在一溶剂中以形成一溶液,该溶剂选自如下组:乙酸、二甲亚砜、N,N-二甲基乙酰胺和上述溶剂的混合物;
(2)通过向步骤(1)的溶液中添加一反溶剂形成SN38晶体,从而获得一悬浮液,该反溶剂选自如下组:1,2-二氯乙烷、丙酮、乙酸乙酯、乙醇和上述溶剂的混合物;
(3)过滤步骤(2)的悬浮液,以获得SN38结晶固体。
优选的,溶解步骤(1)在至少80℃的温度下进行。步骤(2)在温度0-30℃下进行。
表征本发明的新颖性的各种特征在所附的权利要求中特别指出,并形成说明书公开的一部分。为了更好的理解本发明、其操作优势和其获得的具体目标,可以参考附图及其描述部分,其中阐述和描写了本发明的优选实施方式。
附图说明
图1所示为根据本发明一个实施方式的晶体SN38的X-射线粉末衍射图;
图2所示为根据本发明一个实施方式的晶体SN38的红外图谱。
具体实施方式
下列实施例用于阐述本发明,而非用于限制本发明。
实施例1
将SN38(10.53g)和乙酸(158ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。当混合物变成清澈溶液,在至少(NLT)75℃下缓慢加入1,2-二氯乙烷(474ml)。加料完成后,冷却混合物至20-30℃,并在此温度下搅拌一小时。过滤出固体,并用二氯乙烷(53ml)清洗。50℃下真空干燥固体,获得6.51g的SN38。
实施例2
将SN38(39.3g)和乙酸(585ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。当混合物变成清澈溶液,在至少(NLT)75℃下缓慢加入乙酸乙酯(1250ml)。加料完成后,冷却混合物至0-10℃,并在此温度下搅拌一小时。过滤出固体并用乙酸乙酯(160ml)清洗。50℃下真空干燥固体,获得34.95g的SN38。
实施例3
将SN38(0.5g)和二甲基亚砜(DMSO)(5ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。当混合物变成清澈溶液,在至少(NLT)75℃下缓慢加入1,2-二氯乙烷(30ml)。加料完成后,冷却混合物至0-10℃,并在此温度下搅拌一小时。过滤出固体,并用l,2-二氯乙烷(15ml)清洗。50℃下真空干燥固体,获得0.15g的SN38。
实施例4
将SN38(0.5g)和乙酸(7.5ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。冷却溶液至50℃,在至少(NLT)50℃下缓慢加入丙酮(10ml)。加料完成后,冷却混合物至0-10℃,并在此温度下搅拌一小时。过滤出固体并用丙酮(10ml)清洗。50℃下真空干燥固体,获得0.44g的SN38。
实施例5
将SN38(0.5g)和N,N-二甲基乙酰胺(4ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。冷却溶液至35℃,在至少(NLT)35℃下缓慢加入二氯甲烷(15ml)。加料完成后,冷却混合物至0-10℃,并在此温度下搅拌一小时。过滤出固体并用二氯甲烷(10ml)清洗。50℃下真空干燥固体,获得0.46g的SN38。
实施例6
将SN38(0.5g)和乙酸(7.5ml)加入一合适的反应器中。加热获得的悬浮液至至少(NLT)80℃,并在至少(NLT)80℃下搅拌直至所有SN38固体溶解。当混合物变成清澈溶液,在至少(NLT)70℃下缓慢加入乙醇(22.5ml)。加料完成后,冷却混合物至20-30℃,并在此温度下搅拌一小时。过滤出固体并用乙醇(10ml)清洗。50℃下真空干燥固体,获得0.40g的SN38。
上文中每个实施例获得的SN38的X-射线衍射图如图1所示,红外图谱如图2所示。
用于获得图1的XRD测试步骤如下。研细测试样品,并均匀放置在X-射线机器的托盘上,Scintag X2高级衍射仪,以2.00Deg/min的连续扫描速率在范围5.00-40.00(DEG.)和波长1.540562下进行测试。
用于获得图2的IR测试步骤如下。称量大约3mg样品,并将样品均匀分散在300mg干燥KBr中,然后立即通过漫反射记录400-4000CM-1之间的图谱。我们对样品进行单独的测试。IR机器为Nicolet,Magna-IR 560Spectrometer。样品扫描数为32。背景扫描数为32。解析度为4。样品增益为8。镜速率为0.6329。孔径为100。
我们的研究还表明根据上述实施例所制备的晶体SN38产品在25℃和70%相对湿度下稳定一年。
本发明不受上述实施例所限制,上述实施例仅用作举例,但可以在所附的专利权利要求保护范围之内进行各种修改。
Claims (8)
1.一种7-乙基-10-羟基喜树碱的多晶型物,其X-射线衍射图如图1所示。
2.根据权利要求1所述的多晶型物,其红外图谱在3584±2cm-1、3253±2cm-1和1736±2cm-1处有谱带。
3.根据权利要求2所述的多晶型物,其红外图谱还在1653±2cm-1、1514±2cm-1和1173±2cm-1处有谱带。
4.根据权利要求2所述的多晶型物,其红外图谱如图2所示。
5.一种制备如权利要求1所述晶体7-乙基-10-羟基喜树碱的方法,包括:
(1)将粗7-乙基-10-羟基喜树碱溶解在一溶剂中以形成一溶液,其中所述溶解在至少80℃的温度下进行,该溶剂选自如下组:乙酸、二甲亚砜、N,N-二甲基乙酰胺和上述溶剂的混合物;
(2)在0-30℃的温度下通过向步骤(1)的溶液中添加一反溶剂形成7-乙基-10-羟基喜树碱晶体,从而获得一悬浮液,该反溶剂选自如下组:1,2-二氯乙烷、丙酮、乙酸乙酯、乙醇和上述反溶剂的混合物;
(3)过滤步骤(2)的悬浮液,以获得7-乙基-10-羟基喜树碱结晶固体。
6.根据权利要求5所述的方法,其中所述溶剂为乙酸,所述反溶剂选自如下组:1,2-二氯乙烷、乙醇和上述反溶剂的混合物,并且步骤(2)在20-30℃的温度下进行。
7.根据权利要求5所述的方法,其中所述溶剂选自如下组:乙酸、二甲基亚砜、N,N-二甲基乙酰胺和上述溶剂的混合物,所述反溶剂选自如下组:乙酸乙酯、丙酮、1,2-二氯乙烷和上述反溶剂的混合物,并且步骤(2)在0-10℃的温度下进行。
8.一种药物组合物,包含有效量的如权利要求1所述的7-乙基-10-羟基喜树碱的多晶型物和至少一药学上可接受的载体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93709807P | 2007-06-25 | 2007-06-25 | |
US60/937,098 | 2007-06-25 | ||
PCT/US2008/007834 WO2009002489A2 (en) | 2007-06-25 | 2008-06-24 | Crystalline polymorph of 7-ethyl-10-hydroxycamptothecin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101686968A CN101686968A (zh) | 2010-03-31 |
CN101686968B true CN101686968B (zh) | 2012-05-30 |
Family
ID=40186216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800217514A Active CN101686968B (zh) | 2007-06-25 | 2008-06-24 | 7-乙基-10-羟基喜树碱的多晶型物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US8138343B2 (zh) |
EP (1) | EP2170329B1 (zh) |
JP (1) | JP5860213B2 (zh) |
KR (1) | KR101579625B1 (zh) |
CN (1) | CN101686968B (zh) |
AR (1) | AR067168A1 (zh) |
AU (1) | AU2008269148B2 (zh) |
CA (1) | CA2690145C (zh) |
ES (1) | ES2530062T3 (zh) |
NZ (1) | NZ581667A (zh) |
SI (1) | SI2170329T1 (zh) |
WO (1) | WO2009002489A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110237605A1 (en) * | 2010-03-26 | 2011-09-29 | Eric Phillips | Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative |
CN104557961B (zh) * | 2015-01-26 | 2016-06-15 | 山东大学 | 7-乙基-10-羟基喜树碱晶型及其制备方法与应用 |
CN104530067B (zh) * | 2015-01-26 | 2016-03-30 | 山东大学 | 一种7-乙基-10-羟基喜树碱新晶型及其制备方法 |
CN114181238B (zh) * | 2021-12-01 | 2023-03-24 | 苏州大学 | 一种具有荧光活性的7-乙基-10-羟基喜树碱药物前体及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5839684A (ja) * | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 10−置換カンプテシン誘導体の製造法 |
US4473692A (en) | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
JPS5839683A (ja) * | 1981-09-04 | 1983-03-08 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
GB8721383D0 (en) * | 1987-09-11 | 1987-10-21 | Erba Farmitalia | Preparation of methylene derivatives |
GB8801697D0 (en) * | 1988-01-26 | 1988-02-24 | Erba Farmitalia | Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione |
AU5873300A (en) | 1999-07-07 | 2001-01-30 | Pharmacia & Upjohn Company | Process to prepare exemestane |
WO2005070951A1 (en) | 2004-01-16 | 2005-08-04 | Cedarburg Pharmaceuticals, Inc. | Exemestane and its intermediates and methods of making the same |
US20050267141A1 (en) * | 2004-05-28 | 2005-12-01 | Phytogen Life Sciences Inc. | Process to prepare camptothecin derivatives |
US20060046993A1 (en) * | 2004-09-01 | 2006-03-02 | Pharmacia Italia S.P.A. | Crystalline polymorphic form of irinotecan hydrochloride |
ATE446299T1 (de) * | 2005-02-07 | 2009-11-15 | Fermion Oy | Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin |
EP1910269B1 (en) | 2005-08-03 | 2013-09-18 | Avra Laboratories PVT. Ltd. | Method of synthesizing key intermediates for the production of camptothecin derivatives |
-
2008
- 2008-06-24 SI SI200831376T patent/SI2170329T1/sl unknown
- 2008-06-24 JP JP2010514776A patent/JP5860213B2/ja active Active
- 2008-06-24 AU AU2008269148A patent/AU2008269148B2/en active Active
- 2008-06-24 CN CN2008800217514A patent/CN101686968B/zh active Active
- 2008-06-24 KR KR1020097025663A patent/KR101579625B1/ko active IP Right Grant
- 2008-06-24 NZ NZ581667A patent/NZ581667A/en not_active IP Right Cessation
- 2008-06-24 US US12/215,006 patent/US8138343B2/en active Active
- 2008-06-24 WO PCT/US2008/007834 patent/WO2009002489A2/en active Application Filing
- 2008-06-24 CA CA2690145A patent/CA2690145C/en active Active
- 2008-06-24 ES ES08779736.1T patent/ES2530062T3/es active Active
- 2008-06-24 EP EP08779736.1A patent/EP2170329B1/en active Active
- 2008-06-25 AR ARP080102738A patent/AR067168A1/es unknown
Non-Patent Citations (3)
Title |
---|
PHARMACEUTICAL BULLETIN》.1991,第39卷(第6期),1446-1454. * |
SAWADA S ET AL.Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin.《CHEMICAL & * |
SAWADASETAL.SynthesisandAntitumorActivityof20(S)-CamptothecinDerivatives:Carbamate-Linked Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin.《CHEMICAL & PHARMACEUTICAL BULLETIN》.1991 |
Also Published As
Publication number | Publication date |
---|---|
US20090012111A1 (en) | 2009-01-08 |
EP2170329A4 (en) | 2011-08-10 |
EP2170329B1 (en) | 2014-12-17 |
AU2008269148A1 (en) | 2008-12-31 |
SI2170329T1 (sl) | 2015-03-31 |
CA2690145A1 (en) | 2008-12-31 |
CA2690145C (en) | 2016-04-12 |
JP5860213B2 (ja) | 2016-02-16 |
AU2008269148B2 (en) | 2013-02-21 |
KR20100028552A (ko) | 2010-03-12 |
ES2530062T3 (es) | 2015-02-26 |
KR101579625B1 (ko) | 2015-12-22 |
WO2009002489A3 (en) | 2009-03-19 |
WO2009002489A2 (en) | 2008-12-31 |
NZ581667A (en) | 2012-03-30 |
JP2010531356A (ja) | 2010-09-24 |
CN101686968A (zh) | 2010-03-31 |
US8138343B2 (en) | 2012-03-20 |
AR067168A1 (es) | 2009-09-30 |
EP2170329A2 (en) | 2010-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1914212B (zh) | Gabaa激动剂的多晶型 | |
JP6692941B2 (ja) | スガマデックスの製造及び純化方法 | |
CN101686968B (zh) | 7-乙基-10-羟基喜树碱的多晶型物 | |
Wang et al. | Synthesis and structure–activity relationship of berberine analogues in LDLR up-regulation and AMPK activation | |
CN103619852B (zh) | 利福昔明的多晶型物及其制备方法 | |
CN105237536A (zh) | 取代的杂环稠合的γ-咔啉固体 | |
RU2648990C1 (ru) | Кристаллы лобаплатина, способы получения и применения в фармацевтике | |
CN106478723B (zh) | 一种噁唑烷酮类抗菌药物的晶型b及其制备方法和应用 | |
CN106632481A (zh) | 一种噁唑烷酮类抗菌药物的晶型a及其制备方法和应用 | |
CN111393454A (zh) | 米哚妥林的新晶型及其制备方法 | |
CN104140414B (zh) | 阿昔替尼晶型的制备方法 | |
CN102887829A (zh) | 芬戈莫德粘酸盐及其晶体的制备方法和用途 | |
CN103509001B (zh) | 一种埃索美拉唑镁三水合物及其制备方法 | |
CN106478724A (zh) | 一种噁唑烷酮类抗菌药物的晶型c及其制备方法和应用 | |
CN111606816A (zh) | 一种地佐辛晶型及其制备方法 | |
CN105777651A (zh) | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 | |
CN107778295A (zh) | 迈瑞替尼化合物 | |
CN110563644A (zh) | 一种仑伐替尼甲磺酸盐的新晶型 | |
CN107778289B (zh) | 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲氨醋酸盐的多晶型物 | |
CN108409691A (zh) | 一种卡巴他赛晶型hdc-1及其制备方法 | |
CN105566210A (zh) | 一种吡仑帕奈化合物 | |
CN104829577B (zh) | 一种黄芩素γ晶型、其制法和其药物组合物与用途 | |
US20090018356A1 (en) | Crystalline polymorph of exemestane | |
CN113773249A (zh) | 索拉非尼游离碱晶型Form X及其制备方法 | |
CN112752752A (zh) | 一种艾司西酞普兰双羟萘酸盐晶型a 的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |